TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

Saved in:
Bibliographic Details
Title: TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Authors: Plummer R; The Northern Centre for Cancer Care, Freeman Hospital, NE7 7DN Newcastle, UK., Sodergren MH; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK., Hodgson R; MiNA Therapeutics Ltd, W12 0BZ London, UK., Ryan BM; MiNA Therapeutics Ltd, W12 0BZ London, UK., Raulf N; MiNA Therapeutics Ltd, W12 0BZ London, UK., Nicholls JP; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK; MiNA Therapeutics Ltd, W12 0BZ London, UK., Reebye V; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK; MiNA Therapeutics Ltd, W12 0BZ London, UK., Voutila J; MiNA Therapeutics Ltd, W12 0BZ London, UK., Sinigaglia L; MiNA Therapeutics Ltd, W12 0BZ London, UK., Meyer T; Research Department of Oncology, UCL Cancer Institute, University College London, WC1E 6DD London, UK., Pinato DJ; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK; Department of Translational Medicine (DIMET), Università Del Piemonte Orientale 'A. Avogadro', Novara, Italy., Sarker D; Department of Research Oncology, Guys Hospital, Kings College London, SE1 9RT London, UK., Basu B; University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK., Blagden S; Department of Oncology, Oxford University, Churchill Hospital, OX3 7LE Oxford, UK., Cook N; University of Manchester and The Christie NHS Foundation Trust, M20 4BX Manchester, UK., Jeffrey Evans TR; The Beatson West of Scotland Cancer Centre, University of Glasgow, G12 0YN Glasgow, UK., Yachnin J; Centrum Kliniska Cancerstudier, Karolinska University Hospital, 17176 Stockholm, Sweden., Chee CE; National University Hospital, National University Cancer Institute Singapore, Singapore 11928, Singapore., Li D; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA., El-Khoueiry A; Norris Comprehensive Cancer Centre, Keck Medicine, University of Southern California, Los Angeles, CA 90089, USA., Diab M; Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA., Huang KW; National Taiwan University Hospital, Taipei, Taiwan., Pai M; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK., Spalding D; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK., Talbot T; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK., Noel MS; Medstar Georgetown University Hospital, Washington, DC 20007, USA., Keenan B; University of California San Francisco, San Francisco, CA 94143, USA., Mahalingam D; Robert H Lurie Comprehensive Cancer Centre, Northwestern University, Chicago, IL 60611, USA., Song MS; Beckman Research Institute, City of Hope, CA, USA., Grosso M; Veracyte, Marseilles, France., Arnaud D; Veracyte, Marseilles, France., Auguste A; Veracyte, Marseilles, France., Zacharoulis D; Department of General Surgery, University Hospital of Larissa, Larissa, Greece., Storkholm J; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK., McNeish I; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK., Habib R; MiNA Therapeutics Ltd, W12 0BZ London, UK., Rossi JJ; Beckman Research Institute, City of Hope, CA, USA., Habib NA; Department of Surgery & Cancer, Imperial College London, W12 0NN London, UK; MiNA Therapeutics Ltd, W12 0BZ London, UK. Electronic address: nagy.habib@imperial.ac.uk.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Apr 15; Vol. 6 (4), pp. 102041. Date of Electronic Publication: 2025 Mar 31.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2025.102041